Seagen Talks Up 24% Growth, Not About Speculated Merck Buyout

Daiichi Arbitration Is Another Wildcard

 
• By Alaric DeArment
  
Like Merck before it, Seagen kept quiet about a speculated buyout deal between the two companies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business